Table 1. Demographic and baseline characteristics of study patient population.
| None N = 271 | MS N = 230 | NODAT N = 6 | MS/NODATa N = 84 | p-value | |
|---|---|---|---|---|---|
| Age, years (SD) | 43.3 (13.4) | 45.6 (13.0) | 55.8 (14.2) | 51.5 (11.8) | <0.001 |
| Male (%) | 146 (53.9) | 135 (58.7) | 3 (50.0) | 49 (58.3) | 0.70 |
| African American (%) | 33 (12.2) | 30 (13.4) | 1 (16.7) | 21 (25.0) | 0.03 |
| Living donor transplant (%) | 172 (63.5) | 130 (56.5) | 3 (50.0) | 49 (58.3) | 0.39 |
| First transplant (%) | 231 (85.2) | 198 (86.1) | 6 (100) | 74 (88.1) | 0.95 |
| HCV-positive serology (%) | 6 (2.2) | 9 (3.9) | 0 (0) | 4 (4.8) | 0.46 |
| FBGb, mg/dL (SD) | 85.1 (9.3) | 87.3 (8.7) | 87.5 (5.6) | 92.4 (15.2) | <0.001 |
| BMI, kg/m2 (SD) | 24.8 (4.4) | 28.7 (5.9) | 26.8 (7.0) | 30.7 (5.2) | <0.001 |
| Acute rejection, yes (%) | 75 (27.7) | 68 (29.6) | 1 (16.7) | 24 (28.6) | 0.94 |
| CNI at transplant, CsA (%) | 246 (90.8) | 212 (92.2) | 6 (100.0) | 79 (94.1) | 0.93 |
| CNI at last follow-up, CsA (%) | 177 (65.3) | 164 (71.3) | 3 (50.0) | 58 (69.1) | 0.28 |
| CNI trough levels, ng/mL (SD) | |||||
| CsA | 111.3 (24.8) | 115.7 (26.8) | 96.3 (15.0) | 115.0 (22.7) | 0.15 |
| Tac | 6.2 (1.6) | 6.6 (1.5) | 6.5 (0.3) | 7.0 (1.7) | 0.25 |
| Prednisone, mg/d (SD) | 7.5 (2.7) | 7.2 (2.6) | 8.3 (2.6) | 7.1 (2.7) | 0.33 |
| Baseline eGFR, mL/min (SD) | 69.3 (18.1) | 68.1 (19.2) | 61.2 (17.4) | 70.1 (19.1) | 0.58 |
MS, metabolic syndrome; NODAT, new onset diabetes after transplant; CNI, calcineurin inhibitor; CsA, cyclosporine, eGFR, estimated glomerular filtration rate.
a
Patients with both diagnosis.
b
FBG, fasting blood glucose.